Sep 2, 2025, 08:47
SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
Heart BMJ posted on X:
”SUGAR and stents: evaluating long-term percutaneous coronary intervention outcomes in patients with diabetes”
Read the full articlle here.
Diabetes makes coronary disease more severe, with narrower, calcified vessels.
Patients with diabetes face higher risks after PCI — heart attack, stent problems, repeat procedures, death.
Risks exist even in silent or pre-diabetes.
Drug-eluting stents improved outcomes but risk stays higher vs. non-diabetics.
The SUGAR trial tested new stents in diabetes — no clear winner yet, but key insights for care.
Stay updated with Haemostasis Today.
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications
-
Sep 17, 2026, 15:19Conan McIlwrath: The Haemophilia Society Engages With IBCA
-
Sep 17, 2026, 15:06Eleftheria Hatzimichael: A Contemporary Diagnostic Approach to Inherited Microcytic Anemias
-
Sep 17, 2026, 14:51Konstantin Yenkoyan: Emicizumab and the Power of Translational Science
-
Sep 17, 2026, 14:47Zachary Sutton: Translating the 2026 KDIGO Guideline Into Practice
-
Sep 17, 2026, 14:43Leah Williams: Evaluating Medical Device Haemocompatibility Under ISO 10993-4